-
Luye Pharmaceutical rose more than 7%, and the company's new drugs were approved for marketing in November
Time of Update: 2023-01-05
Since the beginning of this month, Luye Pharma has achieved fruitful innovation results, and a number of new drugs have been approved for marketing, including domestic dessulsumab injection, China's original antidepressant new drug Ruoxinlin, etc.
-
Cell: Why women are more likely to develop Alzheimer's
Time of Update: 2022-10-12
"X-linked ubiquitin-specific peptidase 11 increases tauopathy vulnerability in women David KangResearchers at Case Western Reserve University have discovered a mechanism in brain tissue that could explain why women are more likely to develop Alzheimer's.
-
The clinical trial of Zhongsheng Pharmaceutical's oral new crown drug RAY1216 was accepted today's daily limit
Time of Update: 2022-08-15
On the evening of May 11, Zhongsheng Pharmaceutical issued an announcement stating that the clinical trial registration application for the innovative drug RAY1216 tablets of oral anti-new coronavirus 3CL protease inhibitor, Zhongsheng Ruichuang, a holding subsidiary, was accepted by the National Medical Products Administration (NMPA).
-
The Gansu Provincial Food and Drug Administration released the results of drug sampling inspection of 8 batches of drugs that did not meet the requirements
Time of Update: 2022-03-09
The drug does not meet the standard requirements .
Attachment: List of drugs that do not meet the standard requirements in the first phase of drug sampling in Gansu Province in 2022 (8 batches in total)
-
China's pharmaceutical equipment industry has ushered in a period of opportunity and will accelerate its development in three directions
Time of Update: 2022-02-22
On the whole, under the background of the continuous expansion of the market scale, the stricter industry supervision and the intensified competition, the pharmaceutical equipment enterprises are currently adapting to the market demand, accelerating technological innovation, expanding cooperation with foreign countries, and at a higher level, more Improve the manufacturing level and production capacity of China's pharmaceutical equipment on a large scale .
-
Chongqing Drug Administration intends to cancel the Youmei Pharmaceuticals Business License
Time of Update: 2021-08-29
On August 6, Youmei Pharmaceuticals terminated its drug business, and upon the application of the enterprise, the Chongqing Drug Administration planned to cancel its Pharmaceutical Business License .
Attached table: the content of the license to be cancelled
-
Trodelvy receives accelerated approval from the U.S. FDA for the treatment of metastatic urothelial cancer
Time of Update: 2021-07-09
It announced today that the US Food and Drug Administration (FDA) has Accelerated approval of its partner Gilead Sciences (NASDAQ: GILD) Trodelvy® (sacituzumab govitecan-hziy) for the treatment of patients who have previously received platinum-containing chemotherapy and PD-1 or PD-L1 inhibitors Patients with locally advanced or metastatic urothelial carcinoma (mUC) .
-
The first review
Time of Update: 2021-07-07
On May 10, Enhua Pharmaceuticals issued an announcement stating that it had recently received the "Drug Supplementary Application Approval Notice" for "clonazepam tablets" approved and issued by the State Food and Drug Administration, and approved the drug to pass the quality and quality of generic drugs.
Up to now, the company's clonazepam tablets are the first domestic product to pass the consistency evaluation.
-
Kelun takes the lead in imitating a star drug targeting over $4 billion
Time of Update: 2021-03-22
com, there are currently 4 domestic companies that have submitted enzalutamide listing applications under the new classification, including Hausen, Kelun, Qilu, and Shenyang Hongqi Pharmaceutical.
com, there are currently 4 domestic companies that have submitted enzalutamide listing applications under the new classification, including Hausen, Kelun, Qilu, and Shenyang Hongqi Pharmaceutical.
-
Kyushua Pharmaceuticals' $790 million acquisition of Novaral's CDMO subsidiary is on fire
Time of Update: 2021-03-04
After the acquisition is completed, the company will give full play to Suzhou Novarchi's core business advantages, optimize the company's core business advantages in areas such as innovative drug CDMO one-stop service, and meet China's fast-growing commissioned research and development and production needs, Kyushua Pharmaceuticals said in a statement.
-
The U.S. Food and Drug Administration has approved a new treatment for triple negative breast cancer
Time of Update: 2021-03-03
, the U.S. Food and Drug Administration has accelerated approval of treatment for adult patients with triple-negative breast cancer that has spread to other parts of the body.
-
Drug Administration sampling results: These medical devices can not be sold for the time being (with list
Time of Update: 2021-01-08
Pharmaceutical Network November 20, 27 batches of products unqualified November 17, the State Drug Administration issued a national medical device supervision sampling results notice, in the semicondu
-
NMPA approved 31 new drugs in the first half of the year with a minimum time of 139 days
Time of Update: 2020-07-23
Text According to The Insight database, The NMPA approved 212 pharmaceutical batches in the first half of 2020, involving 146 varieties, with 85% of chemicals by variety ingredient category, follow
-
Cinda Biorecoa Whole Human Source Anti-CD47 monoclonal antibody body approved by FDA for drug clinical trial
Time of Update: 2020-06-11
recently, Cinda Bio announced that the Company (developed recombinant whole-human source anti-CD47 monoclonal antibody (research code: IBI-188), has been the United States Food Drug (the Drug
-
FDA issues rare pediatric disease designation for Albireo Pharma's drug A4250
Time of Update: 2020-06-11
PFIC is a sexual, life-threatening liver disease that affects between 50,000 and 100,000 newborns worldwide moderate to severe itching is a common clinical problem in PFIC, which significantly redu
